North Staffordshire Joint Formulary Formulary


	North Staffordshire Joint Formulary North Staffordshire Clinical Commissioning Group Stoke-on-Trent Clinical Commissioning Group

Search

Formulary Chapter 4: Central nervous system - Full Chapter

04.04

CNS stimulants and other drugs used for attention deficit hyperactivity disorder

Atomoxetine (Strattera^®)

Formulary

Atomoxetine (as Atomoxetine hydrochloride) Capsule 10mg
Atomoxetine (as Atomoxetine hydrochloride) Capsule 18mg
Atomoxetine (as Atomoxetine hydrochloride) Capsule 25mg
Atomoxetine (as Atomoxetine hydrochloride) Capsule 40mg
Atomoxetine (as Atomoxetine hydrochloride) Capsule 60mg
Atomoxetine (as Atomoxetine hydrochloride) Capsule 80mg
Atomoxetine (as Atomoxetine hydrochloride) Capsule 100mg

Restriction: Initiation and stabilisation by specialist

Medicines for Children Leaflet: Atomoxetine for ADHD

Link to ESCA

Dexamfetamine Sulfate

Formulary

Dexamfetamine Sulfate Tablet 5mg

Restriction: Initiation and stabilisation by specialist

Link to ESCA

Methylphenidate hydrochloride

Formulary

Restriction: Initiation and stabilisation by specialist

Note Different versions of modified-release preparations may not have the same clinical effect. To avoid confusion between these different formulations of methylphenidate, prescribers should specify the brand to be dispensed.

Medicines for children leaflet: Methylphenidate for ADHD

Link to ESCA

UKMI Q&A: Methylphenidate use for adults with ADHD

Modafinil (Provigil^®)

Formulary

Modafinil Tablet 100mg
Modafinil Tablet 200mg

Restriction: Initiation by specialist

MHRA/CHM advice: Modafinil: potential risk of congenital malformations during pregnancy (February 2020)

NICE NG87: Attention deficit hyperactivity disorder: diagnosis and management

....

Key

	Notes
	Section Title (top level)
	Section Title (sub level)
	First Choice item
	Non Formulary section
	Restricted Drug
	Unlicensed
	Display tracking information
	Link to adult BNF
	Link to children's BNF
	Link to SPCs
	Scottish Medicines Consortium

	Cytotoxic Drug
	Controlled Drug
	High Cost Medicine
	Cancer Drugs Fund
	NHS England
	Homecare
	CCG
	High Cost Drug Approval System

Traffic Light Status Information

Status	Description
	Medicines that can only be prescribed within Secondary Care. Examples of medicines which fall into this category are: Certain new medicines and new indications for older medicines where there is at present no experience of use in Primary Care. Medicines or dressings not available or prescribable in Primary Care. Where a medicine has been classified as Amber E, but an approved shared-care guideline is not yet available
	Medicines which can be prescribed within Secondary Care, but are only suitable for prescribing in Primary Care after specialist referral. There is no need for approved shared care guidelines for medicines in this category. This replaces Amber 2 on the North Staffs Formulary.
	Medicines which can be prescribed within Secondary Care, but are only considered suitable for prescribing in Primary Care under an approved shared-care agreement (ESCA) or Rationale for Initiation, Continuation and Discontinuation (RICaD). This replaces Amber 1 on the North Staffs Formulary
	Medicines which can be prescribed in either Primary or Secondary Care.
	These medicines have been reviewed by the New Medicines Committee and the Area Prescribing Committee and found not to be suitable for inclusion in the Joint Formulary. Inadequate or weak evidence for efficacy No clearly defined local need Lack of long term safety data No perceived benefit over established formulary alternatives Prescribers can consider these medicines where formulary alternatives are unsuitable, ineffective or not tolerated.